Jubilant Ingrevia's $300M agro client faces financial distress
The client for the company's flagship CDMO contract is in trouble. While make-whole provisions exist, the volume ramp-up is now in doubt.
— 4 earlier stories on Jubilant Ingrevia Ltd. →What's new
- The client for the $300M agro contract is in financial distress.
- Management expects at least 20% YoY EBITDA growth for FY27.
- Capex for the current year is set at ₹400-500 crore.
Why this matters
The $300M contract is the primary driver of the company's growth. A distressed client introduces execution risk that threatens the expected volume ramp-up.
What we're watching
- Updates on the client's financial health and order flow.
- Evidence of sequential revenue and profit recovery starting in Q1.
- Progress on the ₹400-500 crore capex program.
The full read
Jubilant Ingrevia faces a test for its $300 million agro CDMO contract. Management disclosed that the client is experiencing financial difficulties, casting doubt on the anticipated volume ramp-up.
Contractual make-whole provisions offer protection.
Despite this, management remains confident in its broader performance, guiding for at least 20% year-on-year EBITDA growth for FY27. The company expects sequential revenue and profit recovery to begin in the first quarter. Meanwhile, the firm continues its investment cycle with a planned capex of ₹400-500 crore for the year. Management also noted that its Pinnacle strategy has delivered 33% higher EBITDA over the last two years, even in the face of price deflation. The open question is whether the client's financial situation will force a revision of the contract's volume expectations.
Questions answered
- What is the status of the $300 million agro contract?
- The contract remains in place, but the customer is experiencing financial difficulties. This creates uncertainty regarding the expected volume ramp-up.
- Does Jubilant Ingrevia have any protection against this client risk?
- Yes, the company confirmed that contractual make-whole provisions are in place to protect its interests.
- What is the company's growth guidance for FY27?
- Management expects at least 20% year-on-year EBITDA growth for the full year.
- When does the company expect a recovery to begin?
- Management anticipates that sequential revenue and profit recovery will start in the first quarter.
- How much is the company spending on capex this year?
- The company has pegged its capex for the current year at ₹400-500 crore.
Jubilant Ingrevia Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on JUBLINGREA →- 26 May 2026 · 6:11 PM IST Jubilant Ingrevia's $300M agro client faces financial distress
- 43d ago Jubilant Ingrevia's call transcript quantifies a ₹3,500 cr CDMO pipeline
- 46d ago Jubilant Ingrevia posts highest profit in 14 quarters on volume recovery
- 46d ago Jubilant Ingrevia hits 14-quarter revenue high, guides for more
- 46d ago Jubilant Ingrevia's FY26 profit grows 10.6%. The numbers were expected.